From May 2014 to January 2017, researchers conducted a systematic review of 33 studies and meta-analyses concerning Entyvio outcomes for ulcerative colitis and Crohn’s disease patients.
Researchers examined a total of 2,857 Entyvio-treated patients. Approximately 1,532 patients had Crohn’s, while 829 had ulcerative colitis. Follow-up periods ranged between 0.5 months and 18 months.
Pooled data showed patients with either disease had low infection rates, malignancies and infusion-related reactions. Researchers said, “This supports the long-term benefit-risk profile of Entyvio, which is consistent with the safety data reported in six clinical trials.”
In another study, researchers examined 567 IBD patients who received Entyvio and possibly used immunosuppressives. .
In that study, data showed patients started Entyvio 4.5 years after their initial diagnosis. Approximately 45.4 percent of patients were never treated with an IM therapy, and 87 percent of patients treated with Entyvio did not use IM drugs after their treatment. Concerning patients treated with an IM therapy, 61 percent who received Entyvio did not continue the IM drugs after.
The 25th UEG Week took place in Barcelona, Spain from Oct. 28 to Nov. 1.
More articles on gastroenterology:
GI leader to know: Dr. Fadel Nammour of Dakota Gastroenterology Clinic
Dr. Nitesh Ratnakar re-elected to ACG governor role — 3 insights
University Medical Center of El Paso treats Barrett’s Esophagus’ patients with ‘freezing balloon’ procedure — 3 facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.